

# **2019 Future of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) R&D Pipeline Drugs and Companies- Analysis of Global Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments**

<https://marketpublishers.com/r/202C427DD6FEN.html>

Date: January 2019

Pages: 120

Price: US\$ 2,199.00 (Single User License)

ID: 202C427DD6FEN

## **Abstracts**

The global demand for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline companies from advancing their products into Phase 3 or Phase 4.

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Report  
Description

The H1 2019 pipeline review report on Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline

compounds.

The Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline guide presents information on all active drugs currently being developed for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline report includes

An overview of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) disease including symptoms, causes, diagnosis and available treatment

options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

## **REASONS TO BUY**

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline progress

Get in detail information of each product with updated information on each

project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

## Contents

### 1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

### 2. GLOBAL PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Report Guide and Research Methodology

### 3. EXECUTIVE SUMMARY

- 3.1 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
- 3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
- 3.4 Companies involved in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline, H1- 2019
- 3.5 Mechanism of Action wise Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Pipeline Candidates

### 4. 480 BIOMEDICAL, INC. PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS

- 4.1 480 Biomedical, Inc. Business Profile
- 4.2 480 Biomedical, Inc. Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 4.2.1 Drug Snapshot
    - 4.2.1.1 Originator
    - 4.2.1.2 Collaborator/Co-Developer
    - 4.2.1.3 Route of Administration
    - 4.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 4.2.1.5 Area
    - 4.2.1.6 Type of Molecular Entity

- 4.3 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

## **5. ALUCENT MEDICAL INC PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 5.1 Alucant Medical Inc Business Profile
- 5.2 Alucant Medical Inc Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 5.2.1 Drug Snapshot
    - 5.2.1.1 Originator
    - 5.2.1.2 Collaborator/Co-Developer
    - 5.2.1.3 Route of Administration
    - 5.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 5.2.1.5 Area
    - 5.2.1.6 Type of Molecular Entity
- 5.3 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

## **6. ANAEROPHARMA SCIENCE, INC. PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 6.1 Anaeropharma Science, Inc. Business Profile
- 6.2 Anaeropharma Science, Inc. Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 6.2.1 Drug Snapshot
    - 6.2.1.1 Originator
    - 6.2.1.2 Collaborator/Co-Developer
    - 6.2.1.3 Route of Administration
    - 6.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 6.2.1.5 Area
    - 6.2.1.6 Type of Molecular Entity
- 6.3 Current Status

- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

## **7. ANGES MG INC PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 7.1 AnGes MG Inc Business Profile
- 7.2 AnGes MG Inc Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 7.2.1 Drug Snapshot
    - 7.2.1.1 Originator
    - 7.2.1.2 Collaborator/Co-Developer
    - 7.2.1.3 Route of Administration
    - 7.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 7.2.1.5 Area
    - 7.2.1.6 Type of Molecular Entity
- 7.3 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

## **8. ANGIOSOMA INC PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 8.1 AngioSoma Inc Business Profile
- 8.2 AngioSoma Inc Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 8.2.1 Drug Snapshot
    - 8.2.1.1 Originator
    - 8.2.1.2 Collaborator/Co-Developer
    - 8.2.1.3 Route of Administration
    - 8.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 8.2.1.5 Area
    - 8.2.1.6 Type of Molecular Entity
- 8.3 Current Status
- 8.4 Drug Overview

- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

## **9. APCETH BIOPHARMA GMBH PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 9.1 apceth Biopharma GmbH Business Profile
- 9.2 apceth Biopharma GmbH Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 9.2.1 Drug Snapshot
    - 9.2.1.1 Originator
    - 9.2.1.2 Collaborator/Co-Developer
    - 9.2.1.3 Route of Administration
    - 9.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 9.2.1.5 Area
    - 9.2.1.6 Type of Molecular Entity
- 9.3 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

## **10. ATHERA BIOTECHNOLOGIES AB PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 10.1 Athera Biotechnologies AB Business Profile
- 10.2 Athera Biotechnologies AB Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 10.2.1 Drug Snapshot
    - 10.2.1.1 Originator
    - 10.2.1.2 Collaborator/Co-Developer
    - 10.2.1.3 Route of Administration
    - 10.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 10.2.1.5 Area
    - 10.2.1.6 Type of Molecular Entity
- 10.3 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action



10.6 Clinical/Pre-clinical Trial Details

10.7 Latest Drug Developments

## **11. ATHERSYS INC PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

11.1 Athersys Inc Business Profile

11.2 Athersys Inc Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details

11.2.1 Drug Snapshot

11.2.1.1 Originator

11.2.1.2 Collaborator/Co-Developer

11.2.1.3 Route of Administration

11.2.1.4 Orphan Drug/Fast Track/Special Designation

11.2.1.5 Area

11.2.1.6 Type of Molecular Entity

11.3 Current Status

11.4 Drug Overview

11.5 Drug Mechanism of Action

11.6 Clinical/Pre-clinical Trial Details

11.7 Latest Drug Developments

## **12. BAYER AG PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

12.1 Bayer AG Business Profile

12.2 Bayer AG Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details

12.2.1 Drug Snapshot

12.2.1.1 Originator

12.2.1.2 Collaborator/Co-Developer

12.2.1.3 Route of Administration

12.2.1.4 Orphan Drug/Fast Track/Special Designation

12.2.1.5 Area

12.2.1.6 Type of Molecular Entity

12.3 Current Status

12.4 Drug Overview

12.5 Drug Mechanism of Action

12.6 Clinical/Pre-clinical Trial Details

## 12.7 Latest Drug Developments

### **13. BETAGENON AB PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

#### 13.1 Betagenon AB Business Profile

#### 13.2 Betagenon AB Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details

##### 13.2.1 Drug Snapshot

###### 13.2.1.1 Originator

###### 13.2.1.2 Collaborator/Co-Developer

###### 13.2.1.3 Route of Administration

###### 13.2.1.4 Orphan Drug/Fast Track/Special Designation

###### 13.2.1.5 Area

###### 13.2.1.6 Type of Molecular Entity

#### 13.3 Current Status

#### 13.4 Drug Overview

#### 13.5 Drug Mechanism of Action

#### 13.6 Clinical/Pre-clinical Trial Details

#### 13.7 Latest Drug Developments

### **14. BIOGENCELL LTD PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

#### 14.1 BiogenCell Ltd Business Profile

#### 14.2 BiogenCell Ltd Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details

##### 14.2.1 Drug Snapshot

###### 14.2.1.1 Originator

###### 14.2.1.2 Collaborator/Co-Developer

###### 14.2.1.3 Route of Administration

###### 14.2.1.4 Orphan Drug/Fast Track/Special Designation

###### 14.2.1.5 Area

###### 14.2.1.6 Type of Molecular Entity

#### 14.3 Current Status

#### 14.4 Drug Overview

#### 14.5 Drug Mechanism of Action

#### 14.6 Clinical/Pre-clinical Trial Details

#### 14.7 Latest Drug Developments

## **15. CARDIOVASCULAR BIOTHERAPEUTICS INC PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 15.1 CardioVascular BioTherapeutics Inc Business Profile
- 15.2 CardioVascular BioTherapeutics Inc Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 15.2.1 Drug Snapshot
    - 15.2.1.1 Originator
    - 15.2.1.2 Collaborator/Co-Developer
    - 15.2.1.3 Route of Administration
    - 15.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 15.2.1.5 Area
    - 15.2.1.6 Type of Molecular Entity
- 15.3 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

## **16. CELULARITY INC PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 16.1 Celularity Inc Business Profile
- 16.2 Celularity Inc Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 16.2.1 Drug Snapshot
    - 16.2.1.1 Originator
    - 16.2.1.2 Collaborator/Co-Developer
    - 16.2.1.3 Route of Administration
    - 16.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 16.2.1.5 Area
    - 16.2.1.6 Type of Molecular Entity
- 16.3 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

## **17. EXODOS LIFE SCIENCES LP PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 17.1 Exodos Life Sciences LP Business Profile
- 17.2 Exodos Life Sciences LP Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 17.2.1 Drug Snapshot
    - 17.2.1.1 Originator
    - 17.2.1.2 Collaborator/Co-Developer
    - 17.2.1.3 Route of Administration
    - 17.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 17.2.1.5 Area
    - 17.2.1.6 Type of Molecular Entity
- 17.3 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

## **18. FORESEE PHARMACEUTICALS CO LTD PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 18.1 Foresee Pharmaceuticals Co Ltd Business Profile
- 18.2 Foresee Pharmaceuticals Co Ltd Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 18.2.1 Drug Snapshot
    - 18.2.1.1 Originator
    - 18.2.1.2 Collaborator/Co-Developer
    - 18.2.1.3 Route of Administration
    - 18.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 18.2.1.5 Area
    - 18.2.1.6 Type of Molecular Entity
- 18.3 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

## **19. HEMOSTEMIX INC PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL**

## **VASCULAR DISEASE (PVD) PIPELINE DETAILS**

19.1 Hemostemix Inc Business Profile

19.2 Hemostemix Inc Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details

19.2.1 Drug Snapshot

19.2.1.1 Originator

19.2.1.2 Collaborator/Co-Developer

19.2.1.3 Route of Administration

19.2.1.4 Orphan Drug/Fast Track/Special Designation

19.2.1.5 Area

19.2.1.6 Type of Molecular Entity

19.3 Current Status

19.4 Drug Overview

19.5 Drug Mechanism of Action

19.6 Clinical/Pre-clinical Trial Details

19.7 Latest Drug Developments

## **20. ID PHARMA CO LTD PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

20.1 ID Pharma Co Ltd Business Profile

20.2 ID Pharma Co Ltd Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details

20.2.1 Drug Snapshot

20.2.1.1 Originator

20.2.1.2 Collaborator/Co-Developer

20.2.1.3 Route of Administration

20.2.1.4 Orphan Drug/Fast Track/Special Designation

20.2.1.5 Area

20.2.1.6 Type of Molecular Entity

20.3 Current Status

20.4 Drug Overview

20.5 Drug Mechanism of Action

20.6 Clinical/Pre-clinical Trial Details

20.7 Latest Drug Developments

## **21. JUVENTAS THERAPEUTICS INC PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 21.1 Juventas Therapeutics Inc Business Profile
- 21.2 Juventas Therapeutics Inc Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 21.2.1 Drug Snapshot
    - 21.2.1.1 Originator
    - 21.2.1.2 Collaborator/Co-Developer
    - 21.2.1.3 Route of Administration
    - 21.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 21.2.1.5 Area
    - 21.2.1.6 Type of Molecular Entity
- 21.3 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

## **22. LIPIMETIX DEVELOPMENT INC PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 22.1 LipimetiX Development Inc Business Profile
- 22.2 LipimetiX Development Inc Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 22.2.1 Drug Snapshot
    - 22.2.1.1 Originator
    - 22.2.1.2 Collaborator/Co-Developer
    - 22.2.1.3 Route of Administration
    - 22.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 22.2.1.5 Area
    - 22.2.1.6 Type of Molecular Entity
- 22.3 Current Status
- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

## **23. MULTIGENE VASCULAR SYSTEMS (MGVS) LTD PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 23.1 MultiGene Vascular Systems (MGVS) Ltd Business Profile
- 23.2 MultiGene Vascular Systems (MGVS) Ltd Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 23.2.1 Drug Snapshot
    - 23.2.1.1 Originator
    - 23.2.1.2 Collaborator/Co-Developer
    - 23.2.1.3 Route of Administration
    - 23.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 23.2.1.5 Area
    - 23.2.1.6 Type of Molecular Entity
- 23.3 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

## **24. NANGIOTX INC PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 24.1 Nangiotx Inc Business Profile
- 24.2 Nangiotx Inc Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 24.2.1 Drug Snapshot
    - 24.2.1.1 Originator
    - 24.2.1.2 Collaborator/Co-Developer
    - 24.2.1.3 Route of Administration
    - 24.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 24.2.1.5 Area
    - 24.2.1.6 Type of Molecular Entity
- 24.3 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

## **25. NOVARTIS AG PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 25.1 Novartis AG Business Profile

## 25.2 Novartis AG Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)

### Drug Details

#### 25.2.1 Drug Snapshot

##### 25.2.1.1 Originator

##### 25.2.1.2 Collaborator/Co-Developer

##### 25.2.1.3 Route of Administration

##### 25.2.1.4 Orphan Drug/Fast Track/Special Designation

##### 25.2.1.5 Area

##### 25.2.1.6 Type of Molecular Entity

### 25.3 Current Status

### 25.4 Drug Overview

### 25.5 Drug Mechanism of Action

### 25.6 Clinical/Pre-clinical Trial Details

### 25.7 Latest Drug Developments

## **26. NUO THERAPEUTICS INC PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

### 26.1 Nuo Therapeutics Inc Business Profile

### 26.2 Nuo Therapeutics Inc Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details

#### 26.2.1 Drug Snapshot

##### 26.2.1.1 Originator

##### 26.2.1.2 Collaborator/Co-Developer

##### 26.2.1.3 Route of Administration

##### 26.2.1.4 Orphan Drug/Fast Track/Special Designation

##### 26.2.1.5 Area

##### 26.2.1.6 Type of Molecular Entity

### 26.3 Current Status

### 26.4 Drug Overview

### 26.5 Drug Mechanism of Action

### 26.6 Clinical/Pre-clinical Trial Details

### 26.7 Latest Drug Developments

## **27. PLURISTEM THERAPEUTICS INC. PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

### 27.1 Pluristem Therapeutics Inc. Business Profile

### 27.2 Pluristem Therapeutics Inc. Peripheral Arterial Disease (PAD)/ Peripheral Vascular



## Disease (PVD) Drug Details

### 27.2.1 Drug Snapshot

#### 27.2.1.1 Originator

#### 27.2.1.2 Collaborator/Co-Developer

#### 27.2.1.3 Route of Administration

#### 27.2.1.4 Orphan Drug/Fast Track/Special Designation

#### 27.2.1.5 Area

#### 27.2.1.6 Type of Molecular Entity

### 27.3 Current Status

### 27.4 Drug Overview

### 27.5 Drug Mechanism of Action

### 27.6 Clinical/Pre-clinical Trial Details

### 27.7 Latest Drug Developments

## **28. G. POHL-BOSKAMP GMBH & CO. KG PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

### 28.1 G. Pohl-Boskamp GmbH & Co. KG Business Profile

### 28.2 G. Pohl-Boskamp GmbH & Co. KG Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details

#### 28.2.1 Drug Snapshot

#### 28.2.1.1 Originator

#### 28.2.1.2 Collaborator/Co-Developer

#### 28.2.1.3 Route of Administration

#### 28.2.1.4 Orphan Drug/Fast Track/Special Designation

#### 28.2.1.5 Area

#### 28.2.1.6 Type of Molecular Entity

### 28.3 Current Status

### 28.4 Drug Overview

### 28.5 Drug Mechanism of Action

### 28.6 Clinical/Pre-clinical Trial Details

### 28.7 Latest Drug Developments

## **29. PROTEON THERAPEUTICS INC PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

### 29.1 Proteon Therapeutics Inc Business Profile

### 29.2 Proteon Therapeutics Inc Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details

- 29.2.1 Drug Snapshot
  - 29.2.1.1 Originator
  - 29.2.1.2 Collaborator/Co-Developer
  - 29.2.1.3 Route of Administration
  - 29.2.1.4 Orphan Drug/Fast Track/Special Designation
  - 29.2.1.5 Area
  - 29.2.1.6 Type of Molecular Entity

29.3 Current Status

29.4 Drug Overview

29.5 Drug Mechanism of Action

29.6 Clinical/Pre-clinical Trial Details

29.7 Latest Drug Developments

### **30. RESVERLOGIX CORPORATION PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

30.1 Resverlogix Corporation Business Profile

30.2 Resverlogix Corporation Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details

- 30.2.1 Drug Snapshot
  - 30.2.1.1 Originator
  - 30.2.1.2 Collaborator/Co-Developer
  - 30.2.1.3 Route of Administration
  - 30.2.1.4 Orphan Drug/Fast Track/Special Designation
  - 30.2.1.5 Area
  - 30.2.1.6 Type of Molecular Entity

30.3 Current Status

30.4 Drug Overview

30.5 Drug Mechanism of Action

30.6 Clinical/Pre-clinical Trial Details

30.7 Latest Drug Developments

### **31. REVEN PHARMACEUTICALS INC PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

31.1 Reven Pharmaceuticals Inc Business Profile

31.2 Reven Pharmaceuticals Inc Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details

- 31.2.1 Drug Snapshot

- 31.2.1.1 Originator
- 31.2.1.2 Collaborator/Co-Developer
- 31.2.1.3 Route of Administration
- 31.2.1.4 Orphan Drug/Fast Track/Special Designation
- 31.2.1.5 Area
- 31.2.1.6 Type of Molecular Entity
- 31.3 Current Status
- 31.4 Drug Overview
- 31.5 Drug Mechanism of Action
- 31.6 Clinical/Pre-clinical Trial Details
- 31.7 Latest Drug Developments

## **32. RHEACELL GMBH & CO. KG PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 32.1 RHEACELL GmbH & Co. KG Business Profile
- 32.2 RHEACELL GmbH & Co. KG Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 32.2.1 Drug Snapshot
    - 32.2.1.1 Originator
    - 32.2.1.2 Collaborator/Co-Developer
    - 32.2.1.3 Route of Administration
    - 32.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 32.2.1.5 Area
    - 32.2.1.6 Type of Molecular Entity
- 32.3 Current Status
- 32.4 Drug Overview
- 32.5 Drug Mechanism of Action
- 32.6 Clinical/Pre-clinical Trial Details
- 32.7 Latest Drug Developments

## **33. SK CHEMICALS CO.,LTD PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 33.1 SK Chemicals Co.,Ltd Business Profile
- 33.2 SK Chemicals Co.,Ltd Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 33.2.1 Drug Snapshot
    - 33.2.1.1 Originator

- 33.2.1.2 Collaborator/Co-Developer
- 33.2.1.3 Route of Administration
- 33.2.1.4 Orphan Drug/Fast Track/Special Designation
- 33.2.1.5 Area
- 33.2.1.6 Type of Molecular Entity
- 33.3 Current Status
- 33.4 Drug Overview
- 33.5 Drug Mechanism of Action
- 33.6 Clinical/Pre-clinical Trial Details
- 33.7 Latest Drug Developments

#### **34. STEMEDICA CELL TECHNOLOGIES INC PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 34.1 Stemedica Cell Technologies Inc Business Profile
- 34.2 Stemedica Cell Technologies Inc Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 34.2.1 Drug Snapshot
    - 34.2.1.1 Originator
    - 34.2.1.2 Collaborator/Co-Developer
    - 34.2.1.3 Route of Administration
    - 34.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 34.2.1.5 Area
    - 34.2.1.6 Type of Molecular Entity
- 34.3 Current Status
- 34.4 Drug Overview
- 34.5 Drug Mechanism of Action
- 34.6 Clinical/Pre-clinical Trial Details
- 34.7 Latest Drug Developments

#### **35. SYMIC BIOMEDICAL INC PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 35.1 Symic Biomedical Inc Business Profile
- 35.2 Symic Biomedical Inc Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 35.2.1 Drug Snapshot
    - 35.2.1.1 Originator
    - 35.2.1.2 Collaborator/Co-Developer

- 35.2.1.3 Route of Administration
- 35.2.1.4 Orphan Drug/Fast Track/Special Designation
- 35.2.1.5 Area
- 35.2.1.6 Type of Molecular Entity
- 35.3 Current Status
- 35.4 Drug Overview
- 35.5 Drug Mechanism of Action
- 35.6 Clinical/Pre-clinical Trial Details
- 35.7 Latest Drug Developments

### **36. VESSL THERAPEUTICS LTD PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 36.1 VESSL Therapeutics Ltd Business Profile
- 36.2 VESSL Therapeutics Ltd Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 36.2.1 Drug Snapshot
    - 36.2.1.1 Originator
    - 36.2.1.2 Collaborator/Co-Developer
    - 36.2.1.3 Route of Administration
    - 36.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 36.2.1.5 Area
    - 36.2.1.6 Type of Molecular Entity
- 36.3 Current Status
- 36.4 Drug Overview
- 36.5 Drug Mechanism of Action
- 36.6 Clinical/Pre-clinical Trial Details
- 36.7 Latest Drug Developments

### **37. VIROMED CO LTD PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 37.1 ViroMed Co Ltd Business Profile
- 37.2 ViroMed Co Ltd Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 37.2.1 Drug Snapshot
    - 37.2.1.1 Originator
    - 37.2.1.2 Collaborator/Co-Developer
    - 37.2.1.3 Route of Administration

- 37.2.1.4 Orphan Drug/Fast Track/Special Designation
- 37.2.1.5 Area
- 37.2.1.6 Type of Molecular Entity
- 37.3 Current Status
- 37.4 Drug Overview
- 37.5 Drug Mechanism of Action
- 37.6 Clinical/Pre-clinical Trial Details
- 37.7 Latest Drug Developments

## **38. YUYU PHARMA INC PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) PIPELINE DETAILS**

- 38.1 Yuyu Pharma Inc Business Profile
- 38.2 Yuyu Pharma Inc Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details
  - 38.2.1 Drug Snapshot
    - 38.2.1.1 Originator
    - 38.2.1.2 Collaborator/Co-Developer
    - 38.2.1.3 Route of Administration
    - 38.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 38.2.1.5 Area
    - 38.2.1.6 Type of Molecular Entity
- 38.3 Current Status
- 38.4 Drug Overview
- 38.5 Drug Mechanism of Action
- 38.6 Clinical/Pre-clinical Trial Details
- 38.7 Latest Drug Developments

## **20. LATEST PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) DRUG PIPELINE DEVELOPMENTS, 2019**

## **21. APPENDIX**

- 21.1 About Us
- 21.2 Sources and Methodology
- 21.3 Contact Information

## I would like to order

Product name: 2019 Future of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) R&D Pipeline Drugs and Companies- Analysis of Global Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/202C427DD6FEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/202C427DD6FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970